201 related articles for article (PubMed ID: 24743641)
1. Elevated hydrogen sulfide levels in vitreous body and plasma in patients with proliferative diabetic retinopathy.
Ran R; Du L; Zhang X; Chen X; Fang Y; Li Y; Tian H
Retina; 2014 Oct; 34(10):2003-9. PubMed ID: 24743641
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
Ma Y; Zhang Y; Zhao T; Jiang YR
Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
[TBL] [Abstract][Full Text] [Related]
3. The impact of ranibizumab on the level of intercellular adhesion molecule type 1 in the vitreous of eyes with proliferative diabetic retinopathy.
Yan Y; Zhu L; Hong L; Deng J; Song Y; Chen X
Acta Ophthalmol; 2016 Jun; 94(4):358-64. PubMed ID: 26285163
[TBL] [Abstract][Full Text] [Related]
4. Plasma and vitreous selenium concentrations in patients with type 2 diabetes and diabetic retinopathy.
Wang C; Ran R; Jin X; Zhu X
Medicine (Baltimore); 2022 Sep; 101(39):e30877. PubMed ID: 36181067
[TBL] [Abstract][Full Text] [Related]
5. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
6. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.
Matsumoto M; Suzuma K; Maki T; Kinoshita H; Tsuiki E; Fujikawa A; Kitaoka T
Am J Ophthalmol; 2012 May; 153(5):896-902.e1. PubMed ID: 22265145
[TBL] [Abstract][Full Text] [Related]
7. Comparison of before versus after intravitreal bevacizumab injection, growth factor levels and fibrotic markers in vitreous samples from patients with proliferative diabetic retinopathy.
Ozer F; Tokuc EO; Albayrak MGB; Akpinar G; Kasap M; Karabas VL
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1899-1906. PubMed ID: 35028761
[TBL] [Abstract][Full Text] [Related]
8. A cross-sectional study of vitreous and serum high mobility group box-1 levels in proliferative diabetic retinopathy.
Shen Y; Cao H; Chen F; Suo Y; Wang N; Xu X
Acta Ophthalmol; 2020 Mar; 98(2):e212-e216. PubMed ID: 31421026
[TBL] [Abstract][Full Text] [Related]
9. Levels of Interleukin 27 and Interleukin 35 in the Serum and Vitreous of Patients with Proliferative Diabetic Retinopathy.
Yan A; You H; Zhang X
Ocul Immunol Inflamm; 2018; 26(2):273-279. PubMed ID: 27537610
[TBL] [Abstract][Full Text] [Related]
10. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.
Citirik M; Kabatas EU; Batman C; Akin KO; Kabatas N
Ophthalmic Res; 2012; 47(1):7-12. PubMed ID: 21691136
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy.
Li B; Li MD; Ye JJ; Chen Z; Guo ZJ; Di Y
Chin Med J (Engl); 2020 Mar; 133(6):664-669. PubMed ID: 32068603
[TBL] [Abstract][Full Text] [Related]
12. Elevated LRP6 levels correlate with vascular endothelial growth factor in the vitreous of proliferative diabetic retinopathy.
Gao X; Ma K; Lu N; Xu Y; Hong T; Peng X
Mol Vis; 2015; 21():665-72. PubMed ID: 26120271
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Ip MS; Domalpally A; Sun JK; Ehrlich JS
Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
Diabetic Retinopathy Clinical Research Network*
JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902
[TBL] [Abstract][Full Text] [Related]
15. Elevation of angiogenic factor Cysteine-rich 61 levels in vitreous of patients with proliferative diabetic retinopathy.
You JJ; Yang CM; Chen MS; Yang CH
Retina; 2012 Jan; 32(1):103-11. PubMed ID: 21822163
[TBL] [Abstract][Full Text] [Related]
16. Elevated protein carbonyl and HIF-1α levels in eyes with proliferative diabetic retinopathy.
Loukovaara S; Koivunen P; Inglés M; Escobar J; Vento M; Andersson S
Acta Ophthalmol; 2014 Jun; 92(4):323-7. PubMed ID: 23718695
[TBL] [Abstract][Full Text] [Related]
17. Hydrogen sulfide serves as a biomarker in the anterior segment of patients with diabetic retinopathy.
Han Y; Zhang X; Zhou Z; Yu M; Wang Q; Yao J; Han Y
Int Ophthalmol; 2020 Apr; 40(4):891-899. PubMed ID: 31894458
[TBL] [Abstract][Full Text] [Related]
18. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy.
Ogata N; Nishikawa M; Nishimura T; Mitsuma Y; Matsumura M
Am J Ophthalmol; 2002 Sep; 134(3):348-53. PubMed ID: 12208245
[TBL] [Abstract][Full Text] [Related]
19. Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment.
Al Kahtani E; Xu Z; Al Rashaed S; Wu L; Mahale A; Tian J; Abboud EB; Ghazi NG; Kozak I; Gupta V; Arevalo JF; Duh EJ
Eye (Lond); 2017 Apr; 31(4):529-536. PubMed ID: 27886182
[TBL] [Abstract][Full Text] [Related]
20. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy.
Mohan N; Monickaraj F; Balasubramanyam M; Rema M; Mohan V
J Diabetes Complications; 2012; 26(5):435-41. PubMed ID: 22699109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
